Azenta
AZTA · NYSE · Healthcare · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$593.8M
Net margin
-9.4%
ROE
-3.3%
Revenue CAGR (2y)
+3.8%
EPS (FY2025)
-1.22
Net profit (FY2025)
$-55.8M
Ask MarketChacha about AZTA
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Sep 1, 2026
Azenta shares fell 3.31% with no new company-specific catalyst reported on Sept 1; the move follows the late-August CEO transition announcement and appears to reflect broader market or sector trading.
- Jul 28, 2026
No specific catalyst identified for the move; Azenta shares rose with the broader market or sector amid no new company-specific news or filings on July 28.
· confidence: low - Jul 24, 2026
Azenta shares fell 3.29% with no company-specific news or filings today; the move appears to reflect broader market or sector trading.
· confidence: low - Jul 23, 2026
No clear company-specific catalyst today; the stock rose with broader market/sector moves after the July 8 divestiture completion and July 22 earnings call announcement.
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $593.8M | $-55.8M | -1.22 | -9.4% | -3.3% |
| FY2024 | $573.4M | $-164.9M | -3.10 | -28.8% | -9.3% |
| FY2023 | $551.5M | $-14.6M | -0.22 | -2.7% | -0.6% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $161.2M | $2.5M | 0.05 | 1.5% |
| 2026Q1 | $144.8M | $-160.8M | -3.49 | -111.1% |
| 2025Q4 | $148.6M | $-15.4M | -0.34 | -10.4% |
| 2025Q3 | $159.2M | $50.9M | 1.11 | 32.0% |
| 2025Q2 | $143.9M | $-48.0M | -1.05 | -33.4% |
| 2025Q1 | $143.3M | $-47.7M | -1.04 | -33.3% |
| 2024Q4 | $147.4M | $-11.0M | -0.25 | -7.5% |
| 2024Q3 | $150.6M | $-6.6M | -0.14 | -4.4% |
| 2024Q2 | $144.3M | $-6.6M | -0.12 | -4.5% |
| 2024Q1 | $136.4M | $-137.4M | -2.48 | -100.8% |
| 2023Q4 | $142.2M | $-14.3M | -0.25 | -10.0% |
| 2023Q2 | $165.9M | $-1.5M | -0.02 | -0.9% |
| 2023Q1 | $148.4M | $-4.9M | -0.07 | -3.3% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC8/11/2026material
- SEC8/6/2026
- SEC8/4/2026material
- SEC5/8/2026
- SEC5/5/2026material
- SEC4/7/2026material
- SEC4/2/2026material
- SEC3/4/2026material
- SEC2/5/2026
- SEC2/4/2026material
- SEC2/2/2026material
- SEC1/29/2026material
2025
- SEC12/29/2025material
- SEC12/10/2025material
- SEC12/4/2025
- SEC11/21/2025material
- SEC8/6/2025
- SEC8/5/2025material
In the news
- A $63 million sale is now fully paid in cash. Azenta received the final $35 million.Stock Titan · 9/4/2026
- How Investors Are Reacting To Azenta (AZTA) CEO Resignation And Interim Leadership Changesimplywall.st · 8/26/2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTAFinancialContent · 8/25/2026
- Stocks making big moves yesterday: Funko, Hims & Hers Health, Azenta, Strategy, and RUM GroupThe Globe and Mail · 8/25/2026
- Azenta (AZTA) Could Be 35% Overvalued As CEO Change Tests Executionsimplywall.st · 8/24/2026
- Why Azenta (AZTA) Stock Is Down TodayStockStory · 8/24/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.